SCHEMBL11945159

SCHEMBL11945159

O=c1c(Oc2ccc(-c3ccc(O)cc3)cc2)c(N2CCN(S(=O)(=O)Cc3ccccc3)CC2)cnn1-c1cc(F)cc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPBWR1 P48145 4/20 0.43
▸ MCHR1 Q99705 3/20 0.43
▸ MAPT P10636 2/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ GLA P06280 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MAPK1 P28482 1/20 0.39
▸ DCTPP1 Q9H773 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ NCOA2 Q15596 1/20 0.37
▸ NCOA1 Q15788 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ NCOA3 Q9Y6Q9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943730 0.88 MAPT (0.46) MAPTALDH1A1MAPK1DCTPP1LMNA
SCHEMBL11944132 0.85 NPBWR1 (0.51) NPBWR1MCHR1MAPTALDH1A1SMN1; SMN2
SCHEMBL11945412 0.83 MAPT (0.45) MAPTALDH1A1SMN1; SMN2MAPK1DCTPP1
SCHEMBL11945410 0.83 MAPT (0.45) MAPTALDH1A1MAPK1DCTPP1LMNA
SCHEMBL11943720 0.83 MAPT (0.48) MAPTALDH1A1GLASMN1; SMN2MAPK1
SCHEMBL11945139 0.83 MAPT (0.44) MAPTALDH1A1GLASMN1; SMN2MAPK1
SCHEMBL11945133 0.82 MAPT (0.44) MAPTALDH1A1GLASMN1; SMN2MAPK1
SCHEMBL11943641 0.82 MAPT (0.46) MAPTALDH1A1GLASMN1; SMN2DCTPP1
SCHEMBL11945405 0.82 MAPT (0.44) MAPTALDH1A1GLASMN1; SMN2MAPK1
SCHEMBL11945166 0.82 MAPT (0.45) MAPTALDH1A1SMN1; SMN2MAPK1DCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA NPBWR1 4643/4885MCHR1 4513/4885MAPT 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback